MKI67 and neoplasm: Univariate analyses revealed that T stage, N stage, TNM stage, adjuvant therapy, tumor grade (G3/4 vs. G1/2: HR, 1.551; 95% CI, 1.227–1.960; P < 0.001), Ki67 (≥ 40% vs. <40%: HR, 1.327; 95% CI, 1.085–1.622; P = 0.006), and G-Ki67 (II vs. I: HR, 1.308; 95% CI, 1.047–1.633; P = 0.018; III vs. I: HR, 1.821; 95% CI, 1.386–2.391; P < 0.001; Fig. 4) were significantly associated with OS in the developing cohort (Table 3).